Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
AVXS-101
BIOLOGICAL
2 trials
Sponsors
Novartis Gene Therapies
, United BioSource, LLC
Conditions
Spinal Muscular Atrophy
Spinal Muscular Atrophy 1
Phase 1
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
Completed
NCT02122952
Novartis Gene Therapies
Spinal Muscular Atrophy 1
Start: 2014-05-05
End: 2017-12-15
Updated: 2022-09-15
Unknown Phase
AveXis Managed Access Program Cohort for Access to AVXS-101
NCT03955679
United BioSource, LLC
Spinal Muscular Atrophy
Updated: 2020-08-28
Related Papers
Recent developments in gene therapy research in India.
2024-01-01
Long-Term Follow-Up of Onasemnogene Abeparvovec Gene Therapy in Patients with Spinal Muscular Atrophy Type 1 (P7-9.006)
Neurology
2023-04-25
6 citations
Experience of using gene replacement therapy with Zolgensma® (onasemnogene abeparvovec) in real clinical practice in Russia
Neuromuscular Diseases
2022-02-14
13 citations
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
JAMA Neurology
2021-05-17
260 citations
S11 Long-term follow-up of the phase 1 START trial of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1
2021-01-21
3 citations
P07 Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy (SMA): from bench to bedside
2020-10-01
252 Speed to treatment effect in spinal muscular atrophy type 1
Journal of Neurology Neurosurgery & Psychiatry
2019-11-14
P37 Onasemnogene abeparvovec gene-replacement therapy for spinal muscular atrophy: from bench to bedside
2019-11-12
S61 Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): preliminary pulmonary and ventilatory findings from the phase 3 study (STR1VE)
2019-11-12
Study Design of STR1VE-EU, a Phase 3 Trial of AVXS-101 Gene-Replacement Therapy (GRT) in Patients With Spinal Muscular Atrophy Type 1 (SMA1) in Europe
Neuropediatrics
2019-09-01
2 citations
Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Onasemnogene Abeparvovec Phase 1/2 Clinical Trial
Neuropediatrics
2019-09-01
2 citations
Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update
Neuropediatrics
2019-09-01
1 citations
P.066 AVXS-101 gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the phase 1 clinical trial
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
2019-06-01
2 citations
P.060 Time to treatment effect in Spinal Muscular Atrophy Type 1 (SMA1): an indirect comparison of treatments
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
2019-06-01
2 citations
P.061 The value of AVXS-101 gene-replacement therapy for Spinal Muscular Atrophy Type 1 (SMA1)
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
2019-06-01
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy.
2019-05-13
135 citations
Vergleich des Überlebens, der motorischen Funktion und der Meilensteine der motorischen Entwicklung zwischen AVXS-101 und Nusinersen bei der Behandlung von Säuglingen mit spinaler Muskelatrophie Typ I (SMA1)
Nervenheilkunde
2019-05-01
Genetic Replacement Therapy (GRT) Clinical Trial with AVXS-101 in Presymptomatic Spinal Muscular Atrophy (SMA): Design of the Phase III Trial and Baseline Demographic Data
Nervenheilkunde
2019-05-01
Genersatztherapie (Gene Replacement Therapy, GRT) mit AVXS-101 bei spinaler Muskelatrophie Typ I (SMA1): Pivotstudie (STR1VE) – Aktualisierung
Nervenheilkunde
2019-05-01
Phase 1 Study of Intrathecal Administration of AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 2 (SMA2) (STRONG) (P1.6-059)
Neurology
2019-04-09
2 citations
8 more papers not shown